Select therapeutic use:
Indications for RETROVIR IV:
HIV infection, in combination with other antiretrovirals. Prevention of maternal-fetal HIV transmission.
Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg every 4hrs. Renal impairment (CrCL <15mL/min) or on dialysis: 1mg/kg every 6–8hrs. Prevention of maternal-fetal HIV or vertical transmission, severe anemia and/or neutropenia: see full labeling.
Vertical transmission: see full labeling.
Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Monitor for hematologic toxicity; reduce dose or suspend if significant anemia and/or granulocytopenia occurs; transfuse if necessary. Risk of myopathy with prolonged use. Renal or hepatic dysfunction: consider reducing dose. Bone marrow suppression. Risk of liver disease. Women, obesity, prolonged nucleoside exposure, or advanced HIV disease: increased risk of toxicity. Monitor for lipoatrophy; if suspected, switch to alternative therapy. Latex allergy (IV). Elderly. Pregnancy. Nursing mothers: not recommended.
Avoid stavudine, doxorubicin, ribavirin, other nucleoside analogues. Caution with other cytotoxic or myelosuppressive drugs (eg, ganciclovir, interferon-alpha, ribavirin). Potentiated by fluconazole, atovaquone, lamivudine, probenecid, valproic acid, methadone. Monitor phenytoin. May be antagonized by clarithromycin, rifampin, ritonavir, nelfinavir. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Nucleoside analogue (reverse transcriptase inhibitor).
Headache, malaise, nausea, vomiting, anorexia, insomnia, pain, neuropathy, myositis, thrombocytopenia, anemia, neutropenia, myopathy, lactic acidosis, steatosis, hepatomegaly, immune reconstitution syndrome, pancreatitis, others. Children: also fever, cough.
Tabs—contact supplier; Caps—100; Syrup—240mL; IV (20mL/vial)—10